If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
RESPIRATORY
ISSN 2054-3166 Vol 6.1 • November 2018 • europeanmedical-journal.com
INSIDE
Review of
ERS 2018
Paris, France
Contents
EDITORIAL BOARD 4
WELCOME 7
FOREWORD 9
01 CONGRESS REVIEW
Review of ERS 2018, held in Paris, France, 15th–19th September 2018 12
02 INTERVIEWS WITH EMJ RESPIRATORY EDITORIAL BOARD
Prof Dr Catharina Belge 27
Dr Neil Holden
RESPIRATORY ISSN 2054-3166
Contents EDITORIAL BOARD
"A very warm welcome to EMJ Respiratory 6.1,
Editorial Board Editor-in-Chief Dr Antonio Rossi
Aims and Scope The European Medical Journal (EMJ)
EMJ Respir. Chief Executive Officer Spencer Gore
Welcome A very warm welcome to EMJ Respirat
ALPHA 1 ANTITRYPSIN DEFICIENCY (AATD) THERAPIES.
Foreword Dear colleagues and friends, It is my pl
Available now.
Discover inside: Congress Review + Review of
Congress Review Review of the 28th
The involvement of patients at the congress inclu
Access to Green Space During Childhood is Benefici
Trained Artificial Intelligence More Accurate at D
TLD involves the delivery of radiofrequency
Simple Test Accurately Diagnoses Viral Infections
Paracetamol Use Linked to Increased Asthma Risk T
"As we learn more about the genes involved in ast
indicated that inhaled pollution particles c
The researchers intend to continue to follo
Until now there have been very few studies
"This study shows that Ureaplasma infection is
Macitentan: Safe and Effective for Portopulmonary
Xpert® MTB/RIF Ultra*, Xp
Interviews Hear from the newest members of the
precapillary hypertension such as lung diseases o
What are the biggest challenges in PAH? There is
I happened to be walking down a corridor w
AstraZeneca. Rob was an extremely inclusive super
I think, as an academic, the most importan
Research shows that a huge number of
Dr Joanna Porter @DrJoPorter University College L
the similarities between childhood and adult
in ILD. This will not only ensure that we offer p
Introducing the latest Pulmonary Innovations Cor
Focussing on the Patient: Future P
AATD plans to ensure highly specialised healthcar
follow-up, facilitate patient recruitment
diagnosed,9 with an average delay in diagnosis of
No Lab, No Diagnosis: How to Align Testing
the clinical reality is that weekly trips
Table 1: Pooled data from the RAPID randomised co
(79.9%). Other reasons cited included lack of con
antitrypsin deficiency. Respir Med. 2006;100(3):46
Back to Basics in Asthma and COPD: Optimisin
he explained how the properties of these devices
from the first 8 years have been promising,
The Importance of Inhaler Training Across the spe
Patients (%) 100 90 80 70 60 50 40 30 20 10
specific genetic, biomarker, phenotypic, o
Summary Professor Mika Mäkelä Disease control
of budesonide/formoterol fumarate Easyhaler® for
State-of-the-Art Session: Respiratory Infections
Current Knowledge Gaps in the Treatment of Bronch
for the treatment of patients with P. aeruginosa
ciliary clearance, which causes neutrophi
that commonly affects patients who do not h
azithromycin, which has shown moderate in vi
management of adult bronchiectasis. Eur Respir J.
Discovering Asthma Paradigms in an Evolving L
needs of patients with uncontrolled persistent as
IL-33 IL-13 Eosinophil TSLP IL-25 ILC2 cell
manifestations of Type 2 inflammatory disease, inc
A B 100 Type 2 inflammation ↑ F
maintain normal activity levels, and minimis
Asthma phenotyping requires consideration o
risk of comorbid Type 2 inflammatory diseases, whi
31. Whiteley J et al. The burden of atopic
Abstract Reviews Discover the latest research a
Table 1: Outcomes after omalizumab treatment. B
Zn, Ti, Co, Cu, Zr, and Pb (<1.0%); and traces of
Daily Physical Activity in Patients with Severe
In conclusion, this novel study shows significantl
been discharged and always remain at the centre o
Looking to the future, we are excited about the o
were present in 24.19%, and ≥3 comorbidities were
Does Talc Increase Risk of Subsequent Non-
pleural fluid metabolic activity and systemic
References 1. Davies HE et al. Effect of an
when there is little or no pleural fluid present w
<50%.8 Adherence can be improved through mor
chronic obstructive pulmonary disease. Co
prevalence of using inhalers correctly was 31% an
The National Institute for Health and Care Ex
endobronchial valves, namely bronchoscopic lun
Before Zephyr Valve placement
it is very gratifying to have seen the positive
Asthma in Childhood: Current Perspectives
INTRODUCTION Asthma is currently characterised, i
articles consisted of both narrative an
Spirometry is also useful for the assessmen
conducted.31 This study, from the Childhood A
Although the Th2 inflammation hypothesis p
Table 1: Novel biologic therapies currently found
TREATMENT OPTIONS OTHER CURRENT Despite the pros
References 1. Anderson GP. Endotyping asthma
inflammation between mildly allergic 54. asth
Noninvasive Ventilation: Challenges and Pitfalls
patient shows signs of muscle fatigue), NIV is of
ventilator is still in the expiratory phase and i
and a decrease in oxygen diffusion capacity. Appl
invasive ventilation. This leaves increasing FiO
NIV have been shown to have higher tidal v
Box 1: Predictors of noninvasive ventilation fail
6. Brochard L. Intrinsic (or auto-)
2015;30(6):1390-4. 48. L'her E et al. Physiologi
Anti-Programmed Death Receptor 1 Signalling I
Herein, the authors summarise the main ongoing re
The concurrent use of anti-PD1/PD-L1 antibodies w
Table 1: Clinical trials of adjuvant anti-program
Table 2: Clinical trials of neoadjuvant anti-prog
In the neoadjuvant setting, some published d
non-small-cell lung cancer (KEYNOTE-010): A rando
49. Merck Sharp & Dohme Corp. Neoadjuvan
Alternative Exercise and Breathing Intervention
INTRODUCTION Chronic obstructive pulmonary diseas
The purpose of this study was to identify,
Table 2: Description and rationale for alternativ
of 105 participants compared to controls (MD: -3.
Compared to LBE training, WBE improved the endura
be ideal for people with COPD who prefer to exerc
6–24 weeks duration compared with control (fi
the issue of delivery of the interventions
and New Zealand pulmonary rehabilitation guidelin
185-92.
Buyer's Guide > 3D SYSTEMS HEALTHCARE > 3M > ACTE
> MEDI-GLOBE GMBH > MEDISOFT > MEDTRONIC > MEHOW
Never miss an update again. J